Dose-Escalation Studies of Mesenchymal Stromal Cell Therapy for Decompensated Liver Cirrhosis: Phase Ia/Ib Results and Immune Modulation Insights

Researchers conducted sequential Phase Ia/Ib trials using a single-arm, dose-escalation design to evaluate the safety and tolerability of mesenchymal stromal cell therapy in decompensated liver cirrhosis patients while also exploring its immunomodulatory effects and gathering preliminary therapeutic signals.